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Abstract 
Improvement in the outcome of cancer patients who are refractory to currently available 
treatments relies on the development of target-directed therapies. One group of molecular 
targets with potential clinical relevance is a set of protein tyrosine kinases encoded mostly by 
proto-oncogenes and that are frequently deregulated in cancer. Glycogen synthase kinase 3β 
(GSK3β), a serine/threonine protein kinase, has emerged as a therapeutic target for common 
chronic diseases including type 2 diabetes mellitus, neurodegenerative disorders, 
inflammation and osteoporosis. This is based on its currently known functions and primary 
pathologic causalities. GSK3β has well characterized roles in the regulation of gene 
transcription and in oncogenic signaling. We have shown that deregulated GSK3β promotes 
gastrointestinal, pancreatic and liver cancers and glioblastomas. Furthermore, we have 
demonstrated that inhibition of GSK3β attenuates cell survival and proliferation, induces cell 
senescence and apoptosis and sensitizes tumor cells to chemotherapeutic agents and ionizing 
radiation. This has led us to propose GSK3β as a potential therapeutic target in cancer. The 
anti-tumor effects of GSK3β inhibition are mediated by changes in the expression and 
phosphorylation of molecules critical to the regulation of cell cycling, proliferation and 
apoptosis and underlie the pathological role for GSK3β in cancer. Investigation of the 
mechanisms responsible for deregulation of GSK3β and the consequent downstream 
pathologic effects in cancer cells has shed light on the molecular pathways leading to 
tumorigenesis. This will allow exploration of novel therapeutic strategies for cancer that target 
aberrant GSK3β. 
 
Key words: glycogen synthase kinase 3β, molecular target, cancer
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GSK3β AND COMMON DISEASES 
Glycogen synthase kinase 3β (GSK3β) was first identified as a serine/threonine protein 
kinase that regulates glucose/glycogen metabolism under the control of insulin signaling. 
Unlike most protein kinases, GSK3β is active in normal cells and this activity is controlled by 
its subcellular localization, differential phosphorylation and different binding partners. 
GSK3β is inactive when its serine 9 (S9) residue is phosphorylated by the actions of PKA 
(protein kinase A), Akt/PKB (protein kinase B) and/or PKC (protein kinase C). It is active 
when its tyrosine 216 (Y216) residue is phosphorylated either through autophosphorylation or 
through the action of other undetermined kinase(s) [1-3]. This suggests that GSK3β activity is 
regulated by the balance between phosphorylation levels at its S9 and Y216 residues. An 
alternate, phosphorylation-independent mechanism for regulating GSK3β kinase activity has 
also been reported recently [4]. GSK3β not only regulates its primary substrate, glycogen 
synthase (GS), but also influences other fundamental cellular pathways depending on the 
substrates that it phosphorylates and the partners that it binds and interacts with [1-3].   
Accumulating evidence has implicated GSK3β in the development of adult onset, 
chronic diseases including type 2 (non-insulin-dependent) diabetes mellitus (NIDDM) [5-7] 
and Alzheimer’s disease [8, 9]. Recognition that GSK3β promotes inflammation indicates that 
it has pathological roles in a wide range of prevalent diseases including NIDDM and 
neuropsychiatric disorders that involve an inflammatory component [10]. Accordingly, 
GSK3β has emerged as a potential target for the development of drugs against these prevalent 
chronic diseases because of its causative associations with glucose intolerance, neuronal cell 
death and inflammation [11-13]. Another line of investigation has shown that signaling via the 
Wnt/β-catenin pathway facilitates osteogenesis [reviewed in 14-16]. This suggests that 
GSK3β could also be a therapeutic target in osteoporotic bone disorders, since it is a well 
established negative regulator of the Wnt/β-catenin pathway in normal cells (described below). 
In this context, an orally bioavailable GSK3α/β dual inhibitor has been generated as a new 
drug for the treatment of osteoporosis [17]. 
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GSK3β IN CANCER 
Under physiological conditions, GSK3β phosphorylates and thereby triggers the 
degradation of several transcription factors (eg. c-Jun, c-Myc), cell cycle regulators (eg, 
cyclin D1) and proto-oncoproteins such as β-catenin [18, 19]. It is therefore believed to 
inhibit tumor development by interfering with oncogenic signaling pathways (eg. Wnt, 
Hedgehog) [20]. A recent study showing that GSK3β phosphorylates and stabilizes a cell 
cycle regulator p27Kip1 also suggests a tumor suppressor function of GSK3β [21]. Other lines 
of study indicate that GSK3β plays crucial roles in nuclear factor-κB (NF-κB)-mediated cell 
survival [22, 23] and Notch stability and signaling [24]. It is clear that the tumor 
microenvironment, which is largely orchestrated by inflammatory cells, plays an important 
part in cellular neoplastic transformation by fostering tumor cell proliferation, survival and 
invasion [25, 26]. As described above, the close association of GSK3β with inflammation [10] 
suggests a putative pathological role for GSK3β in cancers that involve inflammation. In 
addition, several studies have demonstrated that GSK3β destabilizes the tumor suppressor 
proteins p53 [27, 28] and PTEN (phosphatase and tensin homologue deleted on chromosome 
10) [29], indicating that it may promote cancer. These conflicting notions of the biological 
functions of GSK3β have prompted investigations into the pathologic roles of GSK3β in 
cancer, which is characterized by the irreversible deregulation of cell survival, proliferation 
and differentiation [30]. 
 
GSK3β suppresses tumor growth 
In line with the hypothesis that GSK3β acts as a tumor suppressor [20, 21], a number of 
studies on breast, lung and non-melanoma skin cancers have shown that GSK3β is inactivated 
in cancer tissues and that its activation can induce the apoptosis of cancer cells [31-38, 
reviewed in 39, 40]. It has also been reported that inhibition of GSK3β promotes 
epithelial-mesenchymal transition (EMT), a morphological change hypothesized to associate 
with the invasion and metastasis of tumor cells [41, 42, reviewed in 43-45]. GSK3β can also 
render cancer cells resistant to chemotherapeutic agents [46-50, reviewed in 40]. However, 
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most studies have not evaluated for differences in the biological properties of GSK3β between 
tumor cells and their normal counterparts, nor the consequences of GSK3β inhibition for 
tumor cell survival, proliferation and migration.  
 
Deregulated GSK3β promotes cancer 
We have previously described aberration of the ubiquitin system and its involvement in 
oncogenic Wnt signaling in colorectal cancer [51-56]. Since GSK3β interrupts the canonical 
Wnt pathway by targeting β-catenin for phosphorylation and subsequent ubiquitin-mediated 
degradation [18-20], we directed our research focus towards the study of a putative role for 
GSK3β in cancer. We found increased expression and activity of GSK3β and deregulated 
activity due to imbalance in the differential phosphorylation of S9 and Y216 residues in colon 
cancer cell lines and primary colorectal cancers when compared with their normal 
counterparts. These properties of GSK3β were unrelated to the activation of β-catenin or 
Akt/PKB [57]. The latter is an upstream kinase that phosphorylates the GSK3β S9 residue 
[1-3]. Using a non-radioisotopic in vitro kinase assay (NRIKA) [58], we detected increased 
activity of GSK3β not only in colon cancer cells but also in stomach, pancreatic and liver 
cancer cells and glioblastomas compared to the corresponding normal tissues in which 
GSK3β activity appears to be regulated by differential phosphorylation [59-60]. These 
observations suggest that GSK3β may promote cancer, in contrast to its hypothetical 
anticancer functions. 
A putative pathological role for GSK3β in cancer was demonstrated by our observations 
that its inhibition by pharmacological (small-molecule) inhibitors and RNA interference 
(RNAi) reduced the survival of various cancer cell types and predisposed them to undergo 
apoptosis in vitro [57-60] and in tumor xenografts [60-62]. This led us to propose that 
aberrant GSK3β is a potential therapeutic target for cancer treatment and enabled us to apply 
for domestic and international patents entitled “Suppression of cancer and method for 
evaluating anticancer agent based on the effect of inhibiting GSK3β” [63]. At the same time 
or shortly after our studies on the anti-tumor effects of GSK3β inhibition [57-63], similar 
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observations were reported in prostatic [64, 65], colon [66-68], pancreatic [69, 70], ovarian 
[71], esophageal [72] and medullary thyroid [73, 74] cancers, as well as melanoma [75], 
hematologic malignancies [76-81], malignant gliomas [82, 83], pheochromocytoma and 
paraganglioma [84] (Table 1). As mentioned earlier, although the exact role of GSK3β in 
cancer is still being debated, the overall conclusion from these studies is that GSK3β is likely 
to be a promising therapeutic target in a range of cancer types. 
The hypothesis of oncogene addiction has been proposed as a rationale for molecular 
targeting in cancer treatment. It refers to the observation that a cancer cell, despite its plethora 
of genetic alterations, seemingly exhibits dependence on a single oncoprotein or oncogenic 
pathway for its sustained survival and/or proliferation [85, 86]. This unique state of 
dependence in cancer cells is highlighted by the fact that inactivation of the normal 
counterpart of such oncogene products in normal cells is tolerated without obvious 
consequence. A profound implication of this hypothesis is that acute interruption of crucial 
oncogenic pathways upon which cancer cells are dependent should have major detrimental 
effects on the cancer cells while sparing normal cells that are not similarly addicted to these 
pathways [87]. In our series of studies, inhibition of GSK3β had little effect on cell survival, 
growth, apoptosis or senescence in non-neoplastic cells (eg. HEK293) [57-63]. This is 
supported by reports showing that GSK3β inhibition does not influence the survival or growth 
of human mammary epithelial cells, embryonic lung fibroblasts (WI38) and mouse embryonic 
fibroblasts (NIH-3T3) [69, 73]. Consistent with the physiological roles of GSK3β in Wnt and 
Hedgehog signaling, GSK3β inhibition by pharmacological means can promote embryonic 
stem cell pluripotency [88] and hematopoietic stem cell reconstitution [89]. With respect to 
the oncogene addiction hypothesis [85-87], the selective therapeutic effect of GSK3β 
inhibition against cancer can be explained by our observations on the distinct properties of 
GSK3β in cancer cells [57-63]. In contrast to the effect seen against malignant gliomas [59, 
82, 83], an additional therapeutic benefit of GSK3β inhibition was highlighted by a recent 
study showing that it protects hippocampal neurons from radiation-induced damage, thus 
preventing neurocognitive dysfunction resulting from cranial irradiation [90].  
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GSK3β INHIBITORS ACT AGAINST CANCER 
Different types or classes of GSK3β inhibitors exist based on their structure and 
mechanism of action. Synthetic small-molecule inhibitors have frequently been used for 
investigations into the normal functions and pathological properties of GSK3β, but not for the 
treatment of diseases in clinical settings. Unlike protein tyrosine kinases, there are no 
published studies that have investigated the inhibitory effects of specific antibodies on 
GSK3β function in normal or cancer cells.  
 
Chemical compounds (classical inhibitors) 
The best known non-competitive inhibitor of GSK3β in vitro and in vivo is lithium [91, 
92]. Lithium has been used for more than 50 years as a mood stabilizer and still constitutes 
the primary treatment for bipolar disorder [reviewed in 11-13]. Although the mechanism of 
action is unclear [93], lithium ions inhibit GSK3β activity by competing with magnesium ions 
(Mg2+) and/or increasing phosphorylation of the S9 residue [94]. Some studies have shown 
that increased levels of GSK3β S9 phosphorylation were associated with the therapeutic 
effects of lithium in cancer cells [68, 72-74, 83, 84].  
Valproate (2-propylpentanoic acid), a short-chain fatty acid, is a widely prescribed drug 
for the treatment of epilepsy and bipolar disorder. Several studies [95-98] have shown that 
valproate inhibits histone deacetylase (HDAC), a nuclear enzyme that plays a crucial role in 
chromatin remodeling and that has been implicated in cancer development and progression. 
Inhibition of HDAC leads to changes in the aberrant chromatin structure of cancer cells [99, 
100] and valproate has therefore emerged as a potent anti-cancer agent [101-103]. Clinical 
trials for the treatment of cancer using valproate alone or in combination are ongoing [104, 
105]. Recently, two phase I clinical trials were reported using valproate with the 
methyltransferase inhibitor 5-azacytidine or with the topoisomerase II inhibitor epirubicin 
[106, 107]. These revealed the pharmacokinetic properties and toxicity profiles of valproate in 
cancer patients, as well as reporting rates of stable disease as 39% and partial response as 
22%. In addition to inhibiting HDAC, valproate was also found to directly inhibit GSK3β 
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[108, 109]. Many of the cancer types included in the above mentioned clinical trials with 
valproate [104-107] are also those reported to be responsive to treatment with GSK3β 
inhibitors (Table 1). Therefore, the dual inhibition of HDAC and GSK3β by valproate may 
provide a basis for its anti-cancer activity.   
 
Pharmacological (small-molecule) inhibitors 
More than 30 small-molecule (molecular weight < 600) inhibitors of GSK3β have been 
described to date. Despite their wide chemical diversity, most pharmacological inhibitors 
share the common properties of: (a) they are rather flat, hydrophobic heterocycles; (b) most, 
but not all, act by competing with ATP in the ATP-binding site of the kinase; (c) similar to 
cyclin-dependent kinase (CDK) inhibitors, they bind with the kinase through hydrophobic 
interactions and 2-3 hydrogen bonds [reviewed in 12]. The most frequently used compounds 
for inhibiting GSK3β in cancer cells include SB216763, SB415286, AR-A014418 and BIO 
(Table 1, Figure 1). Of note, it has been reported that AR-A014418 does not significantly 
inhibit 26 closely related protein kinases and is therefore considered highly specific for 
GSK3β [110]. These inhibitors efficiently suppress the proliferation of tumor cells and induce 
their apoptosis in vitro and in tumor xenografts (Table 1) within the reported pharmacological 
doses [12, 110].  
 
Nucleic acid inhibitors (siRNA, shRNA) 
Many of the studies shown in Table 1 used RNAi with small interfering (si) or short 
hairpin (sh) RNA specific to GSK3β in order to evaluate the effect of GSK3β inhibition on 
cancer cells and to investigate the molecular mechanism. Similar to the effects of 
pharmacological inhibitors, the consequences of selective knockdown of GSK3β in cancer 
cells included decreases in cell survival and proliferation and the induction of apoptosis. This 
indicates that both GSK3β expression and activity are necessary for tumor cell survival and 
proliferation in the cancer types shown in Table 1. 
While many studies have suggested that GSK3β is a promising target for drug 
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development [11-13], none of the available small-molecule and nucleic acid inhibitors has yet 
found clinical use for the treatment of diseases such as diabetes mellitus, Alzheimer’s disease, 
inflammation or cancer. This is because of a suspected increased risk for tumorigenesis 
through activation of the Wnt or Hedgehog signaling pathways following GSK3β inhibition, 
as well as the multiple functions of GSK3β in normal cellular metabolism and signaling [1-3, 
11, 18-20, 39, 40]. Previous studies have suggested that GSK3β may have tumor 
suppressor-like functions based on its roles in Wnt/β-catenin signaling, the expression of 
cyclin D1, c-Myc and cyclooxygenase-2 (COX-2), the activity of extracellular 
signal–regulated kinase 1/2 (ERK1/2) and EMT [reviewed in 20, 39, 40]. However, none of 
these studies has conclusively shown neoplastic transformation or tumor development 
following inhibition of GSK3β. The differential effects of GSK3β inhibition on neoplastic 
and non-neoplastic cells [57-63, 69, 73] may occur because of differences in the biological 
properties and functions of the kinase between these cell types. This would support the 
potential clinical application of GSK3β inhibitors for the treatment of cancer types other than 
those of skin, breast and lung. Even if the continuous inhibition of GSK3β was to initiate the 
development of a second cancer in a patient with refractory primary cancer, this would be 
expected to develop clinically only after a considerable lag period. Therefore, any secondary 
tumorigenic potential associated with inhibition of GSK3β may not be of clinical concern 
unless the primary cancer is cured by treatment with the GSK3β inhibitors. 
 
Drugs in clinical use  
Recent structure-based in silico screening has demonstrated that a number of drugs 
currently in clinical use, other than lithium and valproate, may inhibit GSK3β activity. These 
include cimetidine, hydroxychloroquine (an anti-malarial and anti-lupus erythematodes agent), 
gemifloxacin (a new quinolon antibiotic) and olanzapine (an atypical antipsychotic agent) 
(Figure 1), all of which have been found to increase the level of glycogen in the rodent liver 
[111, 112]. Based on their effect against GSK3β, these agents are candidates for potent 
anti-cancer treatments. It has been reported that cimetidine, a histamine H2 receptor 
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antagonist, has anti-tumor activity against colon, stomach and kidney cancers and melanomas. 
This activity appears to involve a number of different mechanisms including inhibition of 
angiogenesis, antagonism of the tumor promoting effect of histamine via activation of H2 
receptor, and enhancement of the host immune response to tumor cells [reviewed in 113]. 




Libraries of natural compounds are sources from which new bioactive molecules are 
identified. Recently, two groups of natural compounds have been shown to inhibit GSK3β 
activity. One group includes tautomycin and tautomycetin, two antifungal antibiotics 
originally isolated from Streptomyces spiroverticillatus and Streptomyces griseochromogens, 
respectively [114, 115]. Tautomycetin was previously reported to inhibit the proliferation of 
colorectal cancer cells through p21Cip/Waf1 induction via the ERK pathway [116]. Both 
tautomycin and tautomycetin suppress the growth of medullary thyroid cancer cells via 
inhibition of GSK3β [74]. The other group includes a number of compounds derived from 
benzofuran-3-yl-(indol-3-yl)maleimides, some of which have been identified as GSK3β 
inhibitors that suppress the proliferation and survival of pancreatic cancer cells [117]. 
 
MOLECULAR BASIS FOR TARGETING GSK3β IN CANCER 
There is considerable interest in the molecular mechanism by which GSK3β exerts a 
putative pathological role in the promotion of tumor cell survival and proliferation (Tables 1 
and 2). Following the discovery by our group of a novel pathological role for GSK3β in 
colorectal cancer [57, 58, 61, 63], several groups have investigated the molecular mechanisms 
by which GSK3β may promote cancer. These include various roles for GSK3β in tumor cell 
resistance to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL), p53 and c-Myc [27, 28, 64, 68], NF-κB-mediated gene transcription [69, 77, 82], 
induction of cyclin D1 expression [71], and the phosphorylation and destabilization of PTEN 
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[29]. GSK3β has also been reported to inhibit colonocyte differentiation by destabilizing the 
transcription factor Hath1 [118] and to facilitate cell migration by binding to h-prune and 
modulating focal adhesions and Rac-1 activity [119-122]. These effects were observed in cells 
of non-neoplastic origin (Table 2) and should therefore also be investigated in cancer cells. In 
all glioblastoma cell lines analyzed to date, inhibition of GSK3β increases the expression of 
p53 and p21 in cells with wild-type p53 and decreases Rb phosphorylation and CDK6 
expression [59]. By analyzing the molecular changes in colon cancer cells transfected with 
GSK3β-specific siRNA, we recently observed a decrease in the level of human telomerase 
reverse transcriptase (hTERT) mRNA following GSK3β depletion. Inhibition of GSK3β 
attenuated telomerase activity and increased β-galactosidase-positive colon cancer cells. 
These effects were associated with increased expression of p53, p21 and JNK1 (c-Jun 
N-terminal kinase 1) and decreases in CDK6 expression and Rb phosphorylation [60]. Our 
findings were consistent with known relationships between such proteins and cell senescence 
[123] and with GSK3β activity [27, 28, 60, 66, 124, 125]. The putative role of GSK3β for 
maintaining the survival of cancer cells may therefore be partly due to effects on hTERT 
expression, telomerase activity and cellular senescence. The latter effect is consistent with a 
recent report that enhanced glycogenesis is directly linked to cellular senescence via the 
modulation of GSK3α/β and glycogen synthase [126]. 
 
CLINICAL IMPLICATIONS 
The use of GSK3β inhibitors to treat chronic diseases requires a strong awareness of 
safety issues. Because GSK3β is a multi-task kinase, its systemic inhibition could lead to 
unexpected side effects arising from the disruption of normal metabolism and/or cellular 
signaling. However, in our preclinical studies and those of others, no detrimental effects were 
observed in rodents treated with GSK3β inhibitors [60-62]. Post-translational modification of 
GSK3β by phosphorylation is thought to underlie the mechanism by which normal cells are 
protected from undesirable effects. Because of the role of GSK3β in regulating various 
proto-oncoproteins, there are concerns that long-term inhibition of GSK3β could increase the 
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risk of cancer development [11, 20, 39, 40]. However, it has been reported that long-term 
administration of lithium, the classical GSK3β inhibitor, did not increase mortality from 
cancer but was instead associated with a reduction in the overall mortality of patients with 
bipolar disorder [127]. Lithium is not thought to be mutagenic or carcinogenic [128] and 
treatment with this compound did not significantly increase the incidence of intestinal tumors 
in genetically predisposed APC mutant mice [129]. This is consistent with the absence of 
primary tumor development in rodents from our preclinical studies [60-62]. Inhibition of 
GSK3β is not sufficient to stabilize β-catenin in normal cells and this seems to occur only 
when one or more transforming events such as APC protein truncation has already taken place 
[130]. Furthermore, in normal cells the critical function of GSK3β in mediating 
Wnt/β-catenin signaling is performed by cell membrane-associated GSK3β. This antagonizes 
the phosphorylation of β-catenin by cytoplasmic GSK3β and thus its degradation [131]. 
Therefore, the available evidence suggests that any increased risk of cancer associated with 
long-term GSK3β inhibition can be avoided by generating new compounds that spatially and 
temporally regulate the expression and activity of GSK3β.  
 
DISCLOSUR OF POTENTIAL CONFLICTS OF INTEREST 
No potential conflicts of interest were disclosed. 
 
ACKNOWLEDGEMENTS 
The authors dedicate this article to the late Dr. Masayoshi Mai whose continuous support 
and encouragement was instrumental for the works carried out in our laboratory. We thank Dr. 
Barry Iacopetta (School of Surgery, University of Western Australia) for critical reading of the 
manuscript. This work was funded in part by Grants-in-Aid for Scientific Research from the 
Japanese Ministry of Education, Science, Sports, Technology and Culture, from the Ministry 
of Health, Labour and Welfare, and from the Japan Society for the Promotion of Science.
 12
Miyashita K, et al. Anti-Cancer Agents in Medicinal Chemistry 2009 
REFERENCES 
[1] Harwood, A. J. Regulation of GSK-3: a cellular multiprocessor. Cell, 2001, 105(7), 
821-824. 
[2] Doble, B. W.; Woodgett, J. R. GSK3: tricks of the trade for a multi-tasking kinase. J. Cell 
Sci., 2003, 116(Pt7), 1175-1186. 
[3] Jope, R. S.; Johnson, G. V. The glamour and gloom of glycogen synthase kinase-3. Trends 
Biochem. Sci., 2004, 29(2), 95-102. 
[4] Baltzis, D.; Pluquet, O.; Papadakis, A. I.; Kazemi, S.; Qu, L. K.; Koromilas, A. E. The 
eIF2α kinases PERK and PKR activate glycogen synthase kinase 3 to promote the 
proteasomal degradation of p53. J. Biol. Chem., 2007, 282(43), 31675-31687. 
[5] Eldar-Finkelman, H.; Krebs, E. G. Phosphorylation of insulin receptor substrate 1 by 
glycogen synthase kinase 3 impairs insulin action. Proc. Natl. Acad. Sci. USA, 1997, 
94(18), 9660-9664. 
[6] Cohen, P. Identification of a protein kinase cascade of major importance in insulin signal 
transduction. Phil. Trans. R. Soc. Lond. Biol. Sci., 1999, 354(1832), 485-495. 
[7] Nikoulina, S. E.; Ciaraldi, T. P.; Mudaliar, S.; Mohideen, P.; Carter, L.; Henry, R. R. 
Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 
diabetes. Diabetes, 2000, 49(2), 263-271.  
[8] Annaert, W.; De Strooper, B. A cell biological perspective on Alzheimer’s disease. Annu. 
Rev. Cell Dev. Biol., 2002, 18, 25-51. 
[9] Bhat, R. V.; Budd, S. L. GSK3β signalling: casting a wide net in Alzheimer’s disease. 
Neurosignals, 2002, 11(5), 251-261. 
[10] Jope, R. S.; Yuskaitis, C. J.; Beurel, E. Glycogen synthase kinase-3 (GSK-3): 
inflammation, diseases and therapeutics. Neurochem. Res., 2007, 32(4-5), 577-595. 
[11] Cohen, P.; Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. 
Drug. Discov., 2004, 3(6), 479-487. 
[12] Meijer, L.; Flajolet, M.; Greengard, P. Pharmacological inhibitors of glycogen synthase 
kinase 3. Trends Pharmacol. Sci., 2004, 25(9), 471-480. 
[13] Kypta, RM. GSK-3 inhibitors and their potential in the treatment of Alzheimer’s disease. 
Expert Opin. Ther. Patents., 2005, 15(10), 1315-1331. 
[14] Hartmann, C. A Wnt canon orchestrating osteoblastogenesis. Trends Cell. Biol., 2006, 
16(3), 151-158. 
[15] Krishnan, V.; Bryant, H. U.; MacDougald, O. A. Regulation of bone mass by Wnt 
signaling. J. Clin. Invest., 2006, 116(5), 1202-1209. 
[16] Ralston, S. H.; de Crombrugghe, B. Genetic regulation of bone mass and susceptibility to 
osteoporosis. Genes Dev., 2006, 20(18), 2492-2506. 
[17] Kulkarni, N. H.; Onyia, J. E.; Zeng, Q.; Tian, X.; Liu, M.; Halladay, D. L.; Frolik, C. A.; 
Engler, T.; Wei, T.; Kriauciunas, A.; Martin, T. J.; Sato, M.; Bryant, H. U.; Ma, Y. L. 
Orally bioavailable GSK-3α/β dual inhibitor increases markers of cellular differentiation 
in vitro and bone mass in vivo. J. Bone Miner. Res., 2006, 21(6), 910-920. 
[18] Polakis, P. The oncogenic activation of β-catenin. Curr. Opin. Genet. Dev., 1999, 9(1), 
15-21. 
 13
Miyashita K, et al. Anti-Cancer Agents in Medicinal Chemistry 2009 
[19] Bienz, M.; Clevers, H. Linking colorectal cancer to Wnt signaling. Cell, 2000, 103(2), 
311-20. 
[20] Manoukian, A. S.; Woodgett, J. R. Role of GSK-3 in cancer: regulation by Wnts and 
other signaling pathways. Adv. Cancer Res., 2002, 84, 203-229. 
[21] Surjit, M.; Lal, S. K. Glycogen synthase kinase-3 phosphorylates and regulates the 
stability of p27kip1 protein. Cell Cycle, 2007, 6(5), 580-588. 
[22] Hoeflich, K. P.; Luo, J.; Rubie, E. A.; Tsao, M. S.; Jin, O.; Woodgett, J. R. Requirement 
for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature, 2000, 
406(6791), 86-90. 
[23] Schwabe, R. F.; Brenner, D. A. Role of glycogen synthase kinase-3 in TNF-α–induced 
NF-κB activation and apoptosis in hepatocytes. Am. J. Physiol. Gastrointest. Liver 
Physiol., 2002, 283(1), G204-211. 
[24] Foltz, Dr.; Santiago, M. C.; Berechid, B. E.; Nye, J. S. Glycogen synthase kinase-3β 
modulates Notch signaling and stability. Curr. Biol., 2002, 12(12), 1006-1011.  
[25] Coussens, L. M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420(6917), 860-867. 
[26] Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Cell, 2005, 
7(6), 513-520. 
[27] Kulikov, R.; Boehme, K. A.; Blattner, C. Glycogen synthase kinase 3-dependent 
phosphorylation of Mdm2 regulates p53 abundance. Mol. Cell Biol., 2005, 25(16), 
7170-7180. 
[28] Qu, L.; Huang, S.; Baltzis, D.; Rivas-Estilla, A. M.; Pluquet, O.; Hatzoglou, M.; 
Koumenis, C.; Taya, Y.; Yoshimura, A.; Koromilas, A. E. Endoplasmic reticulum stress 
induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a 
pathway involving glycogen synthase kinase-3β. Genes Dev., 2004, 18(3), 261-277. 
[29] Maccario, H.; Perera, N. M.; Davidson, L.; Downes, C. P.; Leslie, N. R. PTEN is 
destabilized by phosphorylation on Thr366. Biochem. J., 2007, 405(3), 439-444. 
[30] Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70. 
[31] Dong, J.; Peng, J.; Zhang, H.; Mondesire, W. H.; Jian, W.; Mills, G. B.; Hung, M. C.; 
Meric-Bernstam, F. Role of glycogen synthase kinase 3β in rapamycin-mediated cell 
cycle regulation and chemosensitivity. Cancer Res., 2005, 65(5), 1961-1972.  
[32] Farago, M.; Dominguez, I.; Landesman-Bollag, E.; Xu, X.; Rosner, A.; Cardiff, R. D.; 
Seldin, D. C. Kinase-inactive glycogen synthase kinase 3β promotes Wnt signaling and 
mammary tumorigenesis. Cancer Res., 2005, 65(13), 5792-5801. 
[33] Wang, Y.; Lam, J. B.; Lam, K. S.; Liu, J.; Lam, M. C.; Hoo, R. L.; Wu, D.; Cooper, G. 
J.; Xu, A. Adiponectin modulates the glycogen synthase kinase-3β/β-catenin signaling 
pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. 
Cancer Res., 2006, 66(23), 11462-11470. 
[34] Ding, Q.; He, X.; Xia, W.; Hsu, J. M.; Chen, C. T.; Li, L. Y.; Lee, D. F.; Yang, J. Y.; Xie, 
X.; Liu, J. C.; Hung, M. C. Myeloid cell leukemia-1 inversely correlates with glycogen 
synthase kinase-3β activity and associates with poor prognosis in human breast cancer. 
Cancer Res., 2007, 67(10), 4564-4571.  
[35] Ding, Q.; He, X.; Hsu, J. M.; Xia, W.; Chen, C. T.; Li, L. Y.; Lee, D. F.; Liu, J. C.; 
Zhong, Q.; Wang, X.; Hung, M. C. Degradation of Mcl-1 by β-TrCP mediates glycogen 
 14
Miyashita K, et al. Anti-Cancer Agents in Medicinal Chemistry 2009 
synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol., 
2007, 27(11), 4006-4017.  
[36] Li, J.; Xing, M.; Zhu, M.; Wang, X.; Wang, M.; Zhou, S.; Li, N.; Wu, R.; Zhou, M. 
Glycogen synthase kinase 3β induces apoptosis in cancer cells through increase of 
survivin nuclear localization. Cancer Lett., 2008, 272(1), 91-101.  
[37] Leis, H.; Segrelles, C.; Ruiz, S.; Santos, M.; Paramio, J. M. Expression, localization, and 
activity of glycogen synthase kinase 3β during mouse skin tumorigenesis. Mol. 
Carcinog., 2002, 35(4), 180-185.  
[38] Ma, C.; Wang, J.; Gao, Y.; Gao, T. W.; Chen, G.; Bower, K. A.; Odetallah, M.; Ding, 
M.; Ke, Z.; Luo, J. The role of glycogen synthase kinase 3β in the transformation of 
epidermal cells. Cancer Res., 2007, 67(16), 7756-7764.  
[39] Patel, S.; Woodgett, J. Glycogen synthase kinase-3 and cancer: good cop, bad cop? 
Cancer Cell, 2008, 14(5), 351-353. 
[40] Luo, J. Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer 
chemotherapy. Cancer Lett., 2009, 273(2), 194-200. 
[41] Zhou, B. P.; Deng, J.; Xia, W.; Xu, J.; Li, Y. M.; Gunduz, M.; Hung, M. C. Dual 
regulation of Snail by GSK-3β-mediated phosphorylation in control of 
epithelial–mesenchymal transition. Nat. Cell Biol., 2004, 6(10), 931-940. 
[42] Bachelder, R. E.; Yoon, S.; Franci, C.; de Herreros, A. G.; Mercurio, A. M. Glycogen 
synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the 
epithelial–mesenchymal transition. J. Cell Biol., 2005, 168(1), 29-33. 
[43] Schlessinger, K.; Hall, A. GSK-3β sets Snail’s pace. Nat. Cell Biol., 2004, 6(10), 
913-915. 
[44] Zhou, B. P.; Hung, M. C. Wnt, hedgehog and snail: sister pathways that control by 
GSK-3β and β-Trcp in the regulation of metastasis. Cell Cycle, 2005, 4(6), 772-776. 
[45] Doble, B. W.; Woodgett, J. R. Role of glycogen synthase kinase-3 in cell fate and 
epithelial-mesenchymal transitions. Cells Tissues Organs, 2007, 185(1-3), 73-84. 
[46] Cai, G.; Wang, J.; Xin, X.; Ke, Z.; Luo, J. Phosphorylation of glycogen synthase 
kinase-3β at serine 9 confers cisplatin resistance in ovarian cancer cells. Int. J. Oncol., 
2007, 31(3), 657-662. 
[47] Beurel, E.; Kornprobst, M.; Blivet-Van Eggelpoel, M. J.; Ruiz-Ruiz, C.; Cadoret, A.; 
Capeau, J.; Desbois-Mouthon, C. GSK-3β inhibition by lithium confers resistance to 
chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) 
expression. Exp. Cell. Res., 2004, 300(2), 354-364. 
[48] Beurel, E.; Kornprobst, M.; Blivet-Van Eggelpoel, M. J.; Cadoret, A.; Capeau, J.; 
Desbois-Mouthon, C. GSK-3β reactivation with LY294002 sensitizes hepatoma cells to 
chemotherapy-induced apoptosis. Int. J. Oncol., 2005, 27(1), 215-222. 
[49] Soto-Cerrato, V.; Vinals, F.; Lambert, J. R.; Kelly, J. A.; Perez-Tomas, R. Prodigiosin 
induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3β activity in human 
breast cancer cells. Mol. Cancer Ther., 2007, 6(1), 362-369. 
[50] Li, Z.; Tan, F.; Thiele, C. J. Inactivation of glycogen synthase kinase-3β contributes to 
brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in 
neuroblastoma cells. Mol. Cancer Ther., 2007, 6(12), 3113-3121. 
 15
Miyashita K, et al. Anti-Cancer Agents in Medicinal Chemistry 2009 
[51] Spiegelman, V. S.; Slaga, T. J.; Pagano, M.; Minamoto, T T.; Ronai, Z.; Fuchs, S. Y. 
Wnt/β-catenin signaling induces the expression and activity of βTrCP ubiquitin ligase 
receptor. Mol. Cell, 2000, 5(5), 877-882.  
[52] Ougolkov, A. V.; Yamashita, K.; Mai, M.; Minamoto, T. Oncogenic β-catenin and 
MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology, 
2002, 122(1), 60-71. 
[53] Zhang, B.; Ougolkov, A.; Yamashita, K.; Takahashi, Y.; Mai, M.; Minamoto, T. β-catenin 
and ras oncogenes detect most human colorectal cancer. Clin. Cancer Res., 2003, 9(8), 
3073-3079. 
[54] Ougolkov, A.; Zhang, B.; Yamashita, K.; Bilim, V.; Mai, M.; Fuchs, S. Y.; Minamoto, T. 
Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin and NF-κB in 
colorectal cancer. J. Natl. Cancer Inst., 2004, 96(15), 1161-1170. 
[55] Noubissi, F. K.; Elcheva, I.; Bhatia, N.; Shakoori, A.; Ougolkov, A.; Liu, J.; Minamoto, 
TT.; Ross, J.; Fuchs, S. Y.; Spiegelman, V. S. CRD-BP mediates stabilization of βTrCP1 
and c-myc mRNA in response to β-catenin signalling. Nature, 2006, 441(7095), 898-901. 
[56] Fuchs, S. Y.; Ougolkov, A. V.; Spiegelman, V. S.; Minamoto, T. Oncogenic β-catenin 
signaling networks in colorectal cancer. Cell Cycle, 2005, 4(11), 1522-1539. 
[57] Shakoori, A.; Ougolkov, A.; Yu, Z. W.; Zhang, B.; Modarressi, M. H.; Billadeau, D. D.; 
Mai, M.; Takahashi, Y.; Minamoto, T. Deregulated GSK3β activity in colorectal cancer: 
its association with tumor cell survival and proliferation. Biochem. Biophys. Res. 
Commun., 2005, 334(4), 1365-1373. 
[58] Mai, W.; Miyashita, K.; Shakoori, A.; Zhang, B.; Yu, Z. W.; Takahashi, Y.; Motoo, Y.; 
Kawakami, K.; Minamoto, T. Detection of active fraction of GSK3β in cancer cells by 
non-radioisotopic in vitro kinase assay. Oncology, 2006, 71(3-4), 297-305. 
[59] Miyashita, K.; Kawakami, K.; Nakada, M.; Mai, W.; Shakoori, A.; Fujisawa, H.; Hayashi, 
Y.; Hamada, J.; Minamoto, T. Potential therapeutic effect of glycogen synthase kinase 3β 
inhibition against human glioblastoma. Clin. Cancer Res., 2009, 15(3), 887-897. 
[60] Mai, W.; Kawakami, K.; Shakoori, A.; Kyo, S.; Miyashita, K.; Yokoi, K.; Jin, M. J.; 
Shimasaki, T.; Motoo, Y.; Minamoto, T. Deregulated glycogen synthase kinase-3β 
sustains gastrointestinal cancer cell survival by modulating human telomerase reverse 
transcriptase and telomerase. Clin. Cancer Res., in press. 
[61] Shakoori, A.; Mai, W.; Miyashita, K.; Yasumoto, K.; Takahashi, Y.; Ooi, A.; Kawakami, 
K.; Minamoto, T. Inhibition of GSK3β attenuates proliferation of human colon cancer 
cells in rodents. Cancer Sci., 2007, 98(9), 1388-1393. 
[62] Shimasaki, T T.; Ishigaki, Y.; Tomosugi, N.; Zhao, X.; Kawakami, K.; Minamoto, T.;T  
Motoo, Y. Synergistic effect of gemcitabine and glycogen synthase kinase 3β inhibition 
against human pancreatic cancer cells. J. Gastroenterol., submitted and under review. 
[63] Minamoto, T. Suppression of cancer and method for evaluating anticancer agent based on 
the effect of inhibiting GSK3β．PCT/JP2006/300160; Internal patent applications; No. 
11/794,716/United States; No. 06700524.9/United Kingdom, Germany and France; 
2006-550915/Japan. 
[64] Liao, X.; Zhang, L.; Trasher, J. B.; Du, J.; Li, B. Glycogen synthase kinase-3β 
suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance 
in prostate cancer. Mol. Cancer Ther., 2003, 2(11), 1215-1222. 
 16
Miyashita K, et al. Anti-Cancer Agents in Medicinal Chemistry 2009 
[65] Mazor, M.; Kawano, Y.; Zhu, H.; Waxman, J.; Kypta, R. M. Inhibition of glycogen 
synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. 
Oncogene, 2004, 23(47), 7882-7892. 
[66] Ghosh, J. C.; Altieri, D. C. Activation of p53-dependent apoptosis by acute ablation of 
glycogen synthase kinase-3β in colorectal cancer cells. Clin. Cancer Res., 2005, 11(12), 
4580-4588. 
[67] Tan, J.; Zhuang, L.; Leong, H.; Iyer, N. G.; Liu, E. TT.; Yu, Q. Pharmacologic modulation 
of glycogen synthase kinase-3β promotes p53-dependent apoptosis through a direct 
Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res., 2005, 
65(19), 9012-9020. 
[68] Rottmann, S.; Wang, Y.; Nasoff, M.; Deveraux, Q. L.; Quon, K. C. A TRAIL 
receptor-dependent synthetic lethal relationship between Myc activation and 
GSK3β/FBW7 loss of function. Proc. Natl. Acad. Sci. USA, 2005, 102(42), 
15195-15200. 
[69] Ougolkov, A. V.; Fernandez-Zapico, M. E.; Savoy, D. N.; Urrutia, R. A.; Billadeau, D. D. 
Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene 
transcription and cell survival in pancreatic cancer cells. Cancer Res., 2005, 65(6), 
2076-2081. 
[70] Ougolkov, A. V.; Fernandez-Zapico, M. E.; Bilim, V. N.; Smyrk, T. C.; Chari, S. TT.; 
Billadeau, D. D. Aberrant nuclear accumulation of glycogen synthase kinase-3β in 
human pancreatic cancer: association with kinase activity and tumor proliferation. Clin. 
Cancer Res., 2006, 12(17), 5074-5081. 
[71] Cao, Q.; Lu, X.; Feng, Y-J. Glycogen synthase kinase-3β positively regulates the 
proliferation of human ovarian cancer cells. Cell Res., 2006, 16(7), 671-677. 
[72] Wang, J. S.; Wang, C. L.; Wen, J. F.; Wang, Y. J.; Hu, Y. B.; Ren, H. Z. Lithium inhibits 
proliferation of human esophageal cancer cell line Eca-109 by inducing a G2/M cell cycle 
arrest. World J. Gastroenterol., 2008, 14(25), 3982-3989. 
[73] Kunnimalaiyaan, M.; Vaccaro, A. M.; Ndiaye, M. A.; Chen, H. Inactivation of glycogen 
synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth 
suppression in medullary thyroid cancer cells. Mol. Cancer Ther., 2007, 6(3), 1151-1158. 
[74] Adler, J. T.; Cook, M.; Luo, Y.; Pitt, S. C.; Ju, J.; Li, W.; Shen, B.; Kunnimalaiyaan, M.; 
Chen, H. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer 
cells via inhibition of glycogen synthase kinase-3β. Mol. Cancer Ther., 2009, 8(4), 
914-920. 
[75] Smalley, K. S.; Contractor, R,; Haass, N. K.; Kulp, A. N.; Atilla-Gokcumen, G. E.; 
Williams, D. S.; Bregman, H.; Flaherty, K. T.; Soengas, M. S.; Meggers, E.; Herlyn, M. 
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces 
apoptosis in human melanoma cells. Cancer Res., 2007, 67(1), 209-217. 
[76] De Toni, F.; Racaud-Sultan, C.; Chicanne, G.; Mansat-De Mas, V.; Cariven, C.; Mesange, 
F.; Salles, J. P.; Demur, C.; Alloche, M.; Payrastre, B.; Manenti, S.; Ysebaert, L. A 
cross-talk between the Wnt and the adhesion-dependent signaling pathways governs the 
chemosensitivity of acute myeloid leukemia. Oncogene, 2006, 25(22), 3113-3122. 
[77] Ougolkov, A. V.; Bone, N. D.; Fernandez-Zapico, M. E.; Kay, N. E.; Billadeau, D. D. 
Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear 
factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B 
 17
Miyashita K, et al. Anti-Cancer Agents in Medicinal Chemistry 2009 
cells. Blood, 2007, 110(2), 735-742. 
[78] Holmes, T.; O’Brien, T. A.; Knight, R.; Lindeman, R.; Shen, S.; Song, E.; Symonds, G.; 
Dolnikov, A. Glycogen synthase kinase-3β inhibition preserves hematopoietic stem cell 
activity and inhibit leukemic cell growth. Stem Cells, 2008, 26(5), 1288-1297. 
[79] Holmes, T.; O’Brien, T. A.; Knight, R.; Lindeman, R.; Symonds, G.; Dolnikov, A. The 
role of glycogen synthase kinase-3β in normal haematopoiesis, angiogenesis and 
leukemia. Curr. Med. Chem., 2008, 15(15), 1493-1499. 
[80] Zhou, Y.; Uddin, S.; Zimmerman, T.; Kang, J. A.; Ulaszek, J.; Wickrema, A. Growth 
control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. 
Leukemia Lymphoma, 2008, 49(10), 1945-1953. 
[81] Wang, Z.; Smith, K. S.; Murphy, M.; Piloto, O.; Somervaille, T. C. P.; Cleary, M. L. 
Glycogen synthase kinase-3 in MLL leukaemia maintenance and targeted therapy. Nature, 
2008, 455(7217), 1205-1209. 
[82] Kotliarova, S.; Pastorino, S.; Kovell, L. C.; Kotliarov, Y.; Song, H.; Zhang, W.; Bailey, 
R.; Maric, D.; Zenklusen, J. C.; Lee, J.; Fine, H. A. Glycogen synthase kinase-3 
inhibition induces glioma cell death through c-MYC, nuclear factor-κB, and glucose 
regulation. Cancer Res., 2008, 68(16), 6643-6651. 
[83] Nowicki, M. O.; Dmitrieva, N.; Stein, A. M.; Cutter, J. L.; Godlewski, J.; Saeki, Y.; Nita, 
M.; Berens, M. E.; Sander, L. M.; Newton, H. B.; Chiocca, E. A.; Lawler, S. Lithium 
inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. 
Neuro-Oncol., 2008, 10(5), 690-699. 
[84] Kappes, A.; Vaccaro, A.; Kunnimalaiyaan, M.; Chen, H. Lithium ions: a novel treatment 
for pheochromocytomas and paragangliomas. Surgery, 2007, 141(2), 161-165. 
[85] Weinstein, I. B. Cancer. Addiction to oncogenes—the Achilles’ heal of cancer. Science, 
2002, 297(5578), 63-64. 
[86] Weinstein, I. B.; Joe, A. K. Mechanisms of disease: oncogene addiction—a rationale for 
molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol., 2006, 3(8), 448-457. 
[87] Sharma, S. V.; Settleman, J. Oncogene addiction: setting the stage for molecularly 
targeted cancer therapy. Genes Dev., 2007, 21(24), 3214-3231. 
[88] Sato, N.; Meijer, L.; Skaltsounis, L., Greengard, P.; Brivanlou, A. H. Maintenance of 
pluripotency in human and mouse embryonic stem cells through activation of Wnt 
signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med., 2004, 10(1), 55-63. 
[89] Trowbridge, J. J.; Xenocostas, A.; Moon, R. T.; Bhatia, M. Glycogen synthase kinase-3 
is an in vivo regulator of hematopoietic stem cell repopulation. Nat. Med., 2006, 12(1), 
89-98. 
[90] Thotala, D. K.; Hallahan, D. E.; Yazlovitskaya, E. M. Inhibition of glycogen synthase 
kinase 3β attenuates neurocognitive dysfunction resulting from cranial irradiation. 
Cancer Res., 2008, 68(14), 5859-5868. 
[91] Klein, P. S.; Melton, D. A. A molecular mechanism for the effect of lithium on 
development. Proc. Natl. Acad. Sci. USA, 1996, 93(16), 8455-8489. 
[92] Stambolic, V.; Ruel, L.; Woodgett, J. R. Lithium inhibits glycogen synthase kinase-3 
activity and mimics wingless signalling in intact cells. Curr. Biol., 1996, 6(12), 
1664-1668.  
[93] Phiel, C. J.; Klein, P. S. Molecular targets of lithium action. Annu. Rev. Pharmacol. 
 18
Miyashita K, et al. Anti-Cancer Agents in Medicinal Chemistry 2009 
Toxicol., 2001, 41, 789-813. 
[94] Jope, R. S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. 
Trends Pharmacol. Sci., 2003, 24(9), 441-443. 
[95] Gottlicher, M.; Minucci, S.; Zhu, P.; Kramer, O. H.; Schimpf, A.; Giavara, S.; Sleeman, J. 
P.; Lo Coco, F.; Nervi, C.; Pelicci, P. G.; Heinzel, T. Valproic acid defines a novel class 
of HDAC inhibitors inducing differentiation of transformed cells. EMBO. J., 2001, 
20(24), 6969-6978. 
[96] Phiel, C. J.; Zhang, F.; Huang, E. Y.; Guenther, M. G.; Lazar, M. A.; Klein, P. S. Histone 
deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, 
and teratogen. J. Biol. Chem., 2001, 276(39), 36734-36741. 
[97] Kramer, O. H.; Zhu, P.; Ostendorff, H. P.; Golebiewski, M.; Tiefenbach, J.; Peters, M. 
A.; Brill, B.; Groner, B.; Bach, I.; Heinzel, T.; Göttlicher, M. The histone deacetylase 
inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO. 
J., 2003, 22(13), 3411-3420. 
[98] Gurvich, N.; Tsygankova, O. M.; Meinkoth, J. L.; Klein, P. S. Histone deacetylase is a 
target of valproic acidmediated cellular differentiation. Cancer Res., 2004, 64(3), 
1079-1086. 
[99] Marchion, D. C.; Bicaku, E.; Daud, A. I.; Sullivan, D. M.; Munster, P. N. Valproic acid 
alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res., 
2005, 65(9), 3815-3822. 
[100] Kortenhorst, M. S. Q.; Isharwal, S.; van Diest, P. J.; Chowdhury, W. H.; Marlow, C.; 
Carducci, M. A.; Rodriguez, R.; Veltri, R. W. Valproic acid causes dose- and 
time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. 
Mol. Cancer Ther., 2009, 8(4), 802-808. 
[101] Blaheta, R. A.; Cinatl, J. Jr. Anti-tumor mechanisms of valproate: a novel role for an 
old drug. Med. Res. Rev., 2002, 22(5), 492-511. 
[102] Blaheta, R. A.; Nau, H.; Michaelis, M.; Cinatl, J. Jr. Valproate and valproate-analogues: 
potent tools to fight against cancer. Curr. Med. Chem., 2002, 9(15), 1417-1433. 
[103] Blaheta, R. A.; Michaelis, M.; Driever, P. H.; Cinatl, J. Jr. Evolving anticancer drug 
valproic acid: insights into the mechanism and clinical studies. Med. Res. Rev., 2005, 
25(4), 383-397. 
[104] Atmaca, A.; Al-Batran, S. E.; Maurer, A.; Neumann, A.; Heinzel, T.; Hentsch, B.; 
Schwarz, S. E.; Hövelmann, S.; Göttlicher, M.; Knuth, A.; Jäger, E. Valproic acid 
(VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical 
trial. Br. J. Cancer, 2007, 97(2), 177-182. 
[105] Soriano, A. O.; Yang, H.; Faderl, S.; Estrov, Z.; Giles, F.; Ravandi, F.; Cortes, J.; 
Wierda, W. G.; Ouzounian, S.; Quezada, A.; Pierce, S.; Estey, E. H.; Issa, J. P.; 
Kantarjian, H. M.; Garcia-Manero, G. Safety and clinical activity of the combination of 
5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and 
myelodysplastic syndrome. Blood, 2007, 110(7), 2302-2308. 
[106] Braiteh, F.; Soriano, A. O.; Garcia-Manero, G.; Hong, D.; Johnson, M. M.; Silva, L. de 
P.; Yang, H.; Alexander, S.; Wolff, J.; Kurzrock, R. Phase I study of epigenetic 
modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. 
Cancer Res., 2008, 14(19), 6296-6301. 
[107] Münster, P.; Marchion, D.; Bicaku, E.; Schmitt, M.; Lee, J. H.; DeConti, R.; Simon, G.; 
 19
Miyashita K, et al. Anti-Cancer Agents in Medicinal Chemistry 2009 
Fishman, M.; Minton, S.; Garrett, C.; Chiappori, A.; Lush, R.; Sullivan, D.; Daud, A. 
Phase I trial of histone deacetylase inhibition by valproic acid followed by the 
topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and 
translational study. J. Clin. Oncol., 2007, 25(15), 1979-1985. 
[108] Chen, G.; Huang, L. D.; Jiang, Y. M.; Manji, H. K. The mood-stabilizing agent 
valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem., 1999, 
72(3), 1327-1330. 
[109] Kim, A. J.; Shi, Y.; Austin, R. C.; Werstuck, G. H. Valproate protects cells from ER 
stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase 
kinase-3. J. Cell Sci., 2004, 118(Pt-1), 89-99. 
[110] Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormö, M.; Nilsson, Y.; Radesäter, A. C.; 
Jerning, E.; Markgren, P. O.; Borgegård, TT.; Nylöf, M.; Giménez-Cassina, A.; 
Hernández, F.; Lucas, J. J.; Díaz-Nido, J.; Avila, J. Structural insights and biological 
effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem., 
2003, 278(46), 45937-45945. 
[111] Taha, M. O.; Bustanji, Y.; Al-Ghussein, M. A. S.; Mohammad, M.; Zalloum, H.; 
Al-Masri, I. M.; Atallah, N. Pharmacophore modeling, quantitative structure-activity 
relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3β 
inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin. J. Med. 
Chem., 2008, 51(7), 2062-2077. 
[112] Mohammad, M. K.; Al-masli, I. M.; Taha, M. O.; Al-Ghussein, M. A. S.; AlKhatib, H. 
S.; Najjar, S.; Bustanji, Y. Olanzapine inhibits glycogen synthase kinase-3β: an 
investigation by docking simulation and experimental validation. Eur. J. Pharmacol., 
2008, 584(1), 185-191. 
[113] Lefranc, F.; Yeaton, P.; Brotchi, J.; Kiss, R. Cimetidine, an unexpected anti-tumor agent, 
and its potential for the treatment of glioblastoma (review). Int. J. Oncol., 2006, 28(5), 
1021-1030. 
[114] Cheng, X. C.; Kihara, T.; Kusakabe, H.; Magae, J.; Kobayashi, Y.; Fang, R. P.; Ni, Z. F.; 
Shen, Y. C.; Ko, K.; Yamaguchi, I.; et al. A new antibiotic, tautomycin. J. Antibiot. 
(Tokyo), 1987, 40(6), 907-909. 
[115] Cheng, X. C.; Kihara, T.; Ying, X.; Uramoto, M.; Osada, H.; Kusakabe, H.; Wang, B. 
N.; Kobayashi, Y.; Ko, K.; Yamaguchi, I.; et al. A new antibiotic, tautomycetin. J. 
Antibiot. (Tokyo), 1989, 42(1), 141-144. 
[116] Lee, J. H.; Lee, J. s., Kim, S. E.; Moon, B. S.; Kim, Y. C.; Lee, S. K.; Choi, K. Y. 
Tautomycetin inhibits growth of colorectal cancer cells through p21cip/WAF1 induction 
via the extracellular signal–regulated kinase pathway. Mol. Cancer Ther., 2006, 5(12), 
3222-3231.  
[117] Gaisina, I. N.; Gallier, F.; Ougolkov, A. V.; Kim, K. H.; Kurome, T.; Guo, S.; Holzle, 
D.; Luchini, D. N.; Blond, S. Y.; Billadeau, D. D.; Kozikowski, A. P. From a natural 
product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl) 
maleimides as glycogen synthase kinase 3β inhibitors that suppress proliferation and 
survival of pancreatic cancer cells. J. Med. Chem., 2009, 52(7), 1853-1863. 
[118] Tsuchiya, K.; Nakamura, TT.; Okamoto, R.; Kanai, T.;T  Watanabe, M. Reciprocal 
targeting of Hath1 and β-catenin by Wnt glycogen synthase kinase 3β in human colon 
cancer. Gastroenterology, 2007, 132(1), 208-220. 
 20
Miyashita K, et al. Anti-Cancer Agents in Medicinal Chemistry 2009 
[119] Kobayashi, T.; Hino, S.; Oue, N.; Asahara, TT.; Zollo, M.; Yasui, W.; Kikuchi, A. 
Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal 
adhesions. Mol. Cell. Biol., 2006, 26(3), 898-911. 
[120] Koivisto, L.; Alavian, K.; Häkkinen, L.; Pelech, S.; McCulloch, C. A.; Larjava, H. 
Glycogen synthase kinase-3 regulates formation of long lamellipodia in human 
keratinocytes. J. Cell Sci., 2003, 116(Pt 18), 3749-3760. 
[121] Farooqui, R.; Zhu, S.; Fenteany, G. Glycogen synthase kinase-3 acts upstream of 
ADP-ribosylation factor 6 and Rac1 to regulate epithelial cell migration. Exp. Cell Res., 
2006, 312(9), 1514-1525. 
[122] Vaidya, R. J.; Ray, R. M.; Johnson, L. R. Akt-mediated GSK-3β inhibition prevents 
migration of polyamine-depleted intestinal epithelial cells via Rac1. Cell. Mol. Life Sci., 
2006, 63(23), 2871-2879. 
[123] Kiyono, T. Molecular mechanisms of cellular senescence and immortalization of human 
cells. Expert. Opin. Ther. Targets., 2007, 11(12), 1623-1637. 
[124] Rössig, L.; Badorff, C.; Holzmann, Y.; Zeiher, A. M.; Dimmeler, S. Glycogen synthase 
kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J. 
Biol. Chem., 2002, 277(22), 9684-9689. 
[125] Liu, S.; Yu, S.; Hasegawa, Y.; LaPushin, R.; Xu, H. J.; Woodgett, J. R.; Mills, G. B.; 
Fang, X. Glycogen synthase kinase 3β is a negative regulator of growth factor-induced 
activation of the c-Jun N-terminal kinase. J. Biol. Chem., 2004, 279(49), 51075-51081. 
[126] Seo, Y. H.; Jung, H. J.; Shin, H. T.; Kim, Y. M.; Yim, H.; Chung, H. Y.; Lim, I. K.; 
Yoon, G. Enhanced glycogenesis is involved in cellular senescence via GSK3/GS 
modulation. Aging Cell, 2008, 7(6), 894-907. 
[127] Cohen, Y.; Chetrit, A.; Cohen, Y.; Sirota, P.; Modan, B. Cancer morbidity in psychiatric 
patients: influence of lithium carbonate treatment. Med. Oncol., 1998, 15(1), 32-36. 
[128] Léonard, A.; Hanston, P.; Gerber, G. B. Mutagenicity, carcinogenicity and teratogenicity 
of lithium compounds. Mutat. Res., 1995, 339(3), 131-137. 
[129] Gould, T. D.; Gray, N. A.; Manji, H. K. Effects of a glycogen synthase kinase-3 
inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol. Res., 2003, 
48(1), 49-53. 
[130] Yuan, H.; Mao, J.; Li, L.; Wu, D. Suppression of glycogen synthase kinase activity is 
not sufficient for leukemia enhancer factor-1 activation. J. Biol. Chem., 1999, 274(43), 
30419-30423. 
[131] Zeng, X.; Tamai, K.; Doble, B.; Li, S.; Huang, H.; Habas, R.; Okamura, H.; Woodgett, 
J.; He, X. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. 
Nature, 2005, 438(7069), 873-877. 
 
FIGURE LEGEND 
Figure 1. Chemical structures of small-molecule inhibitors for GSK3β and of drugs in 
clinical use that have been found to inhibit GSK3β activity. 
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Table 1 │ Pathological roles and functions of GSK3β in molecular pathways implicated in human cancer 
Cancer type Types of GSK3β inhibitors 
in vitro or 
in vivo 
 
Pathological roles for GSK3 and underlying mechanisms 
 
Author [Ref.] 
prostate LiCl, SB216763 
siRNA 
in vitro GSK3β renders prostate cancer cells resistant to 
TRAIL-induced apoptosis. 
Liao X [64] 
prostate SB216763, 
SB415286, siRNA
in vitro GSK3β maintains AR activity and prostate cancer cell 
proliferation. 







Deregulated GSK3β expression and activity are associated 
with tumor cell survival and proliferation in CRC by 
mechanism independent of activation of Wnt/β-catenin 
signaling and Akt. GSK3β inhibition attenuates survival and 
proliferation of colon cancer cells by decreasing hTERT 
expression and telomerase activity and inducing cell 
senescence. 
Shakoori A [57] 
Mai W [58, 60] 
Shakoori A [61] 
colon  LiCl, TDZD8, 
SB216763, siRNA
in vitro GSK3β functions against activation of p53-dependent 
apoptosis in colon cancer cells. 
Ghosh JC [66] 
colon  LiCl, SB216763, 
SB415286, 
LY2119301 
in vitro GSK3β functions against activation of p53-dependent 
apoptosis through a direct Bax-mediated mitochondrial 
pathway in colon cancer cells. 
Tan J [67] 
colon  LiCl, siRNA in vitro GSK3β functions against colon cancer cell apoptosis by 
inhibiting a TRAIL receptor-dependent synthetic lethal 
relationship between Myc activation and FBW7 loss of 
function.  






GSK3β participates in NF-κB-mediated gene transcription 
and cell survival in pancreatic cancer cells. GSK3β inhibition 
attenuates proliferation of pancreatic cancer cell xenografts by 
inhibiting nuclear localization and activation of NF-κB. 
Ougolkov A  
[69, 70] 
pancreatic  AR-A014418 
SB216763, siRNA
in vitro Deregulated GSK3β expression and activity are associated 
with tumor cell survival and proliferation. GSK3β renders 
pancreatic cancer cells resistant to a chemotherapeutic agent 
(gemcitabine) by inhibiting p53 and c-Myc-mediated 
Mai W [58, 60] 
Shimasaki T [62] 
 - 1 -
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pro-apoptotic pathways.  
stomach  AR-A014418 
SB216763, siRNA
in vitro Deregulated GSK3β expression and activity are associated 
with tumor cell survival and proliferation. 
Mai W [58, 60] 
liver  AR-A014418 
SB216763, siRNA
in vitro Deregulated GSK3β expression and activity are associated 
with tumor cell survival and proliferation. 
Mai W [57, 59] 
ovarian  LiCl in vitro 
tumor 
xenografts 
GSK3β positively regulates the proliferation of human 
ovarian cancer cells by increasing the expression of cyclin 
D1. 
Cao Q [71] 
oesophageal  LiCl in vitro GSK3β inhibition decreases the proliferation of a human 
oesophageal cancer cell line by inducing G2/M cell cycle 
arrest. 
Wang JS [72] 
medullary thyroid  LiCl, SB216763 in vitro 
tumor 
xenografts 
GSK3β is regulated by raf-1 pathway and is associated with 
proliferation of medullary thyroid cancer cells. 
Kunnimalaiyaan M 
[73], Adler JT [74] 
melanoma LiCl, SB216763, 
DW1, DW2, 
DW1/2 
in vitro GSK3β functions against activation of p53-dependent 
apoptosis in human melanoma cells. 
Smalley KS [75] 






in vitro GSK3β renders AML cells resistant to a chemotherapeutic 
agent (daunorubicin) by activating NF-κB. 
De Toni F [76]  
leukemia (B-cell 
CLL) 
AR-A014418 ex vivo Inhibition of GSK3β abrogates NF-κB binding to its target 
gene promoters through an epigenetic mechanism and 
enhances apoptosis in CLL B cells ex vivo.  
Ougolkov AV [77] 
leukemia BIO in vitro 
ex vivo 
GSK3β inhibition suppresses leukemic cell growth via the 
induction of apoptosis mediated by down-regulation of 
survivin. 
Holmes T [78, 79] 
multiple myeloma TDZD in vitro GSK3β enhances myeloma cell growth by phosphorylation of 
FOXO proapoptotic transcription factor resulting in its 
inactivation. 
Zhou Y [80] 
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GSK3β selectively maintains the survival and proliferation of 
MLL leukemia cells by decreasing p27Kip1.  
Wang Z [81] 







GSK3β inhibition leads to reduced glioma cell survival and 
clonogenicity by induction of c-Myc-dependent apoptosis, 
inactivation of intracellular NF-κB and alteration of 
intracellular glucose metabolism. 
Kotliarova S [82] 





GSK3β inhibitors decrease the migration of glioma cells in 
vitro and in brain tissue slices. 





in vitro GSK3β inhibition attenuates the survival and proliferation of 
glioblastoma cells and sensitizes them to chemotherapeutic 
agents and ionizing radiation by activating p53-p21 and 
CDK6-Rb tumor suppressor pathways. 
Miyashita K [59] 
pheochromocytoma, 
paraganglioma 
LiCl in vitro Treatment with lithium resulted in dose-dependent inhibition 
of GSK3β in tumor cells and reduced their proliferation. 
Kappes A [84] 
     
ADP, adenosine diphosphate; AML, acute myeloid leukemia; AR, androgen receptor; CDK/Cdk, cyclin-dependent kinase; CLL, chronic 
lymphocytic leukemia; CRC, colorectal cancer; FBW7, F-box/WD40 domain protein 7; FOXO, Forkhead box O; GSK3(β), glycogen synthase 
kinase 3(β); hTERT, human telomerase reverse transcriptase; MLL, myeloid/lymphoid or mixed lineage; NF-κB, nuclear factor-κB; shRNA, 
short hairpin RNA; siRNA, small interfering RNA; TRAIL, tumor necrosis factor (TNF)-related apoptosis-inducing ligand. 
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Table 2 │ Proposed functions of GSK3β in the molecular pathogenesis of human cancers 
 




Pathological roles for GSK3 and underlying mechanisms 
 
Author [Ref.] 
NS Mdm2, p53, p21 GSK3β phosphorylates the central domain of Mdm2 resulting in Mdm2- 
dependent p53 degradation and decreased p21 expression. 
Kulikov R [27] 
NS p53 ER stress induces p53 cytoplasmic localization (inactivation) and prevents 
p53-dependent apoptosis by a pathway involving GSK3β. 
Qu L [28] 
NS p21Cip1 GSK3β phosphorylates p21Cip1 at Thr-57 residue within the Cdk binding 
domain and facilitates its degradation. 
Rössig L [124] 
glioblastoma  PTEN GSK3 phosphorylates a tumor suppressor protein, PTEN, at Thr-366 residue 
leading to its destabilization. 
Maccario H [28] 
colon cancer  Hath1 GSK3β inhibits colonocyte differentiation by destabilizing the transcription 
factor, Hath1. 
Tsuchiya K [118] 
NS JNK GSK3β serves as a physiological switch to specifically repress JNK activation 
in response to LPA, sphingosine-1-phosphatase, or EGF.  
Liu S [125] 
NS h-prune, cell 
motility/migration 
GSK3β interacts with h-prune, cooperatively facilitating the disassembly of 
focal adhesions by activating FAK and Rac, and promoting cell migration.  
Kobayashi T [115] 
NS Lamellipodia, cell 
migration 
GSK3 enhances formation of long lamellipodia in human keratinocytes and 
cell migration. 
Koivisto L [120] 
NS ADP-ribosylation 
factor 6, Rac1 
GSK3 facilitates cell migration mediated by ADP-ribosylation factor 6 and 
Rac1 in response to hepatocyte growth factor/scatter factor. 
Farooqui R [121] 
NS Rac1 GSK3β increases intestinal epithelial cell migration by activating Rac1 in 
response to Akt inhibition. 
Vaidya RJ [122] 
Cdk, cyclin-dependent kinase; EGF, epidermal growth factor; ER, endoplasmic reticulum; FAK, focal adhesion kinase; GSK3(β), glycogen 
synthase kinase 3(β); JNK, c-Jun N-terminal kinase; LPA, lysophosphatidic acid; Mdm 2, mouse double minute 2; NS, not specified; PTEN, 
phosphatase and tensin homologue deleted on chromosome 10; 
